LUNGevity Foundation Announces Free Webinar on Dermatologic Side Effects of Anti-Cancer Therapies, July 27, 2011

WASHINGTON, July 25, 2011 /PRNewswire-USNewswire/ -- LUNGevity Foundation and GRACE  are pleased to partner in providing an upcoming one-hour webinar on Wednesday, July 27th at 6 p.m. Eastern/3 p.m. Pacific, on the subject of prevention and management of skin, nail, and hair-related side effects of common lung cancer treatments.  This program will be led by Dr. Mario Lacouture, a dermatologist now running a busy clinic at Memorial Sloan-Kettering Cancer Center in New York City,  who is arguably the leading expert on dermatologic side effects of EGFR inhibitors and other anti-cancer therapies.  As usual, the presentation will be followed by an online Q&A session.

Dr. Lacouture is an Associate Member of Memorial Sloan-Kettering's faculty and Co-chair of the Skin Toxicity Study Group of the Multinational Association of Supportive Care in Cancer, an international organization devoted to the understanding of side effects in cancer patients.

Registration is free (www.lungevity.org) and for anyone unable to make the live presentation or who would just like to review the program later, these presentations and the question and answer sessions will be made into podcasts that will be freely available.

About LUNGevity Foundation
The mission of LUNGevity Foundation is to have a meaningful and immediate impact on improving lung cancer survival rates, ensure a higher quality of life for lung cancer patients, and provide a community for those impacted by lung cancer.

In order to accomplish its mission, LUNGevity funds the most promising research into the early detection and successful treatment of lung cancer. LUNGevity also supports the largest national grassroots lung cancer network.

LUNGevity seeks to inspire the nation to commit to ending lung cancer.

About Lung Cancer

• Lung cancer impacts 1 in 14 Americans and is the number-one cancer killer. 
• About 60 percent of Americans diagnosed with lung cancer are either never-smokers or former smokers.
• Less than 16 percent of people diagnosed with lung cancer survive 5 years post-diagnosis because of limited early detection opportunities.
• There is no widely available, effective early diagnostic test available today.

SOURCE LUNGevity Foundation